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Background: CYP2C19 genotype influences antiplatelet response to clopidogrel; treatment with double-dose has been suggested in patients 
carrying CYP2C19 loss-of-function allele.We sought to determine the antiplatelet effect of adding cilostazol to standard-dose clopidogrel (75mg/d) 
(TRIPLE) compared to doubling-dose of clopidogrel (150mg/d) (DOUBLE) and the influence of genetic polymorphisms in patients with type 2 DM 
(T2DM) undergoing PCI.
Methods: T2DM patients were treated with TRIPLE (n=41) or DOUBLE (n=39) following PCI. Conventional aggregometry and VerifyNow were 
performed at baseline and 30-days; CYP3A5*3, CYP2C19*2/*3 and ABCB1 C3435T were genotyped. The primary endpoint was the absolute change 
in 20μM ADP-induced maximal platelet aggregation (ΔMPA20) after switching from standard therapy to DOUBLE or TRIPLE.
Results: Patients treated with TRIPLE had greater ΔMPA20 (22.9±11.6% vs.12.7±15.5%; difference, 10.2%; 95% confidence interval, 4.2-16.3%; 
p<0.001). Carriage of one (` coefficient, -5.418; SE, 4.674; p=0.162) and two CYP2C19 loss-of-function allele(s) (` coefficient, -8.261; SE, 2.708; 
p=0.007) were associated with lower ΔMPA20 in DOUBLE-treated patients (Figure A), but not in TRIPLE-treated patients (Figure B).
Conclusions: Among T2DM patients undergoing PCI, adding cilostazol to standard dual antiplatelet therapy achieves greater platelet inhibition as 
compared to 150mg/d clopidogrel, and this effect is not influenced by genetic polymorphisms.
 
